The function of calmodulin as a biological regulator is linked to the level of free Ca2+ in the cell, and there is evidence that calmodulin may itself be involved in the control of the movements of cellular Ca2+. Malignant hyperpyrexia, on the other hand, is caused by a disturbance in the level of myoplasmic Ca2+. We have investigated the possibility that calmodulin may be involved in malignant hyperpyrexia by studying the trifluoperazine-induced inhibition of calmodulin activation by phosphodiesterase, using crude and purified calmodulin preparations from control and MH-susceptible pigs. No abnormality was found in the pattern of either calmodulin activation or trifluoperazine-induced inhibition in MH muscle.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0006-2944(84)90081-4DOI Listing

Publication Analysis

Top Keywords

malignant hyperpyrexia
12
calmodulin involved
8
trifluoperazine-induced inhibition
8
calmodulin activation
8
calmodulin
7
calmodulin malignant
4
hyperpyrexia function
4
function calmodulin
4
calmodulin biological
4
biological regulator
4

Similar Publications

Anesthesia and Myopathies of Horses.

Vet Clin North Am Equine Pract

December 2024

Department of Clinical Sciences, Auburn University College of Veterinary Medicine, 1130 Wire Road, Auburn, AL 36849, USA; College of Veterinary Medicine, 1220 Wire Road, Auburn, AL 36849, USA.

Pre-existing muscle disorders in horses can often be subtle and may only become evident during or after anesthesia. Advancements in veterinary medicine, along with increased knowledge and research in this field, help minimize anesthesia-related problems. Adequate preanesthesia assessment, early disease diagnosis, and proper management are crucial in minimizing risks to the neuromuscular system during general anesthesia.

View Article and Find Full Text PDF

Malignant ascites (MA), a common and serious complication of various cancers in the abdominal cavity, originates from the extensive infiltration, metastasis, and growth of cancer cells in or on the abdominal cavity, leading to abnormal accumulation of fluid in the abdominal cavity and the formation of MA. MA seriously reduces the quality of life of cancer patients, shortens their survival period, and generally has a poor prognosis. Modern medicine has developed various strategies for the treatment of MA, including targeted supportive treatment, diuretic treatment, abdominal paracentesis, surgical intervention, and intraperitoneal administration therapy.

View Article and Find Full Text PDF

Mutations in the skeletal isoform of the ryanodine receptor 1 (RyR1) pose grave risks during anesthesia or treatment with succinylcholine muscle relaxants. These can trigger a potentially lethal malignant hyperthermia (MH) episode via intracellular calcium increase mainly from RyR1 channel leakage. Dantrolene is the only known treatment option to prevent death.

View Article and Find Full Text PDF

Background: Modulated electro-hyperthermia (mEHT) is unique due to its combination of thermal and non-thermal effects.

Method: This report summarizes the literature on the effects of mEHT observed in vitro and in vivo.

Results: The thermal and electrical heterogeneity of tissues allows the radiofrequency signal to selectively target malignant tissue.

View Article and Find Full Text PDF

BACKGROUND Malignant hyperthermia (MH) and anesthesia-induced rhabdomyolysis (AIR) are rare, yet life-threatening complications that need prompt therapeutic actions and logistic preparedness for treatment success. Both conditions are triggered by general anesthetics, particularly volatiles and depolarizing muscle relaxants. In comparison with MH, which is an inherited pharmacogenomic disease of calcium channel receptor subpopulation and arises only after trigger exposure, AIR has been described mostly in patients with muscular dystrophies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!